These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1117 related articles for article (PubMed ID: 18301895)

  • 21. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.
    Hoffmann J; Vitale I; Buchmann B; Galluzzi L; Schwede W; Senovilla L; Skuballa W; Vivet S; Lichtner RB; Vicencio JM; Panaretakis T; Siemeister G; Lage H; Nanty L; Hammer S; Mittelstaedt K; Winsel S; Eschenbrenner J; Castedo M; Demarche C; Klar U; Kroemer G
    Cancer Res; 2008 Jul; 68(13):5301-8. PubMed ID: 18593931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
    Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
    Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
    Iwahashi T; Okochi E; Ariyoshi K; Watabe H; Amann E; Mori S; Tsuruo T; Ono K
    Cancer Res; 1993 Nov; 53(22):5475-82. PubMed ID: 8106147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
    Broggini-Tenzer A; Sharma A; Nytko KJ; Bender S; Vuong V; Orlowski K; Hug D; O'Reilly T; Pruschy M
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25694444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
    Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
    Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
    Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
    Ramachandran C; Wellham LL
    Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.
    O'Reilly T; McSheehy PM; Kawai R; Kretz O; McMahon L; Brueggen J; Bruelisauer A; Gschwind HP; Allegrini PR; Lane HA
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):625-39. PubMed ID: 19784839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
    Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
    Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the microenvironment for radiosensitization by patupilone.
    Bley CR; Jochum W; Orlowski K; Furmanova P; Vuong V; McSheehy PM; Pruschy M
    Clin Cancer Res; 2009 Feb; 15(4):1335-42. PubMed ID: 19228735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
    Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
    Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue.
    Li LH; DeKoning TF; Kelly RC; Krueger WC; McGovren JP; Padbury GE; Petzold GL; Wallace TL; Ouding RJ; Prairie MD
    Cancer Res; 1992 Sep; 52(18):4904-13. PubMed ID: 1516047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
    Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study.
    Mok TS; Choi E; Yau D; Johri A; Yeo W; Chan AT; Wong C
    Oncology; 2006; 71(3-4):292-6. PubMed ID: 17657173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
    Narla RK; Chen CL; Dong Y; Uckun FM
    Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue.
    Chen LM; Liang YJ; Zhang X; Su XD; Dai CL; Wang FP; Yan YY; Tao LY; Fu LW
    Anticancer Res; 2009 Nov; 29(11):4597-604. PubMed ID: 20032409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.